STOCK TITAN

ZyVersa Therapeutics Inc - ZVSA STOCK NEWS

Welcome to our dedicated news page for ZyVersa Therapeutics (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZyVersa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZyVersa Therapeutics's position in the market.

Rhea-AI Summary
ZyVersa Therapeutics, Inc. announces the publication of a scientific paper in Alzheimer's & Dementia: Translational Research & Clinical Interventions, demonstrating the role of the inflammasome/ASC speck pathway in synaptic degeneration in Alzheimer’s Disease. The paper highlights the potential of ZyVersa’s Inflammasome ASC Inhibitor IC 100 in targeting ASC specks to block damaging inflammation in the central nervous system and peripheral tissues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed journal, Acta Neuropathologica Communications, demonstrating that inflammasome activation enhances cancer metastasis to the brain in women with TNBC. The company is developing Inflammasome ASC Inhibitor IC 100, which can inhibit up to 12 different inflammasomes and their associated ASC specks which perpetuate damaging inflammation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces 2024 outlook and development plans for first-in-class drugs targeting renal and inflammatory diseases. Co-Founder and CEO, Stephen C. Glover, discusses the potential of Cholesterol Efflux Mediator VAR 200 to improve kidney function and reduce kidney disease progression, as well as plans for Phase 2a trial with VAR 200 and completion of GLP toxicology studies with Inflammasome ASC Inhibitor IC 100.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (ZVSA) is developing two proprietary product platforms targeting renal and inflammatory diseases. The Cholesterol Efflux MediatorTM VAR 200 is designed to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression. The Inflammasome ASC Inhibitor IC 100 is designed to inhibit multiple inflammasome pathways to attenuate initiation and perpetuation of damaging inflammation pathogenic in numerous inflammatory diseases. ZyVersa has announced that Noble Capital Markets has initiated company-sponsored equity research coverage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces corporate outlook and anticipated milestones for 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.32%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces participation in BIO Partnering @ JPM event, highlighting plans for a Phase 2a clinical trial with Cholesterol Efflux Mediator VAR 200 and development of Inflammasome ASC Inhibitor IC 100.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.06%
Tags
conferences
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces the selection of George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD). The trial is expected to begin in the first quarter of 2024, marking a major milestone in the development of VAR 200 and providing valuable insights for other planned renal indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces publication of an article demonstrating elevated plasma NLRP3 inflammasomes and proinflammatory cytokines in early-stage Diabetic Kidney Disease (DKD). The company is developing Inflammasome ASC Inhibitor IC 100 to attenuate disease progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.26%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced a public offering of 4,000,000 shares of common stock and accompanying Series A and Series B warrants, resulting in gross proceeds of approximately $5.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.26%
Tags
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces the publication of an article in the peer-reviewed journal, Diabetes, demonstrating that AIM2 and NLRP3 inflammasome activation contributes to the development of atherosclerosis in two different animal models of type 1 diabetes. Diabetic animals demonstrated activation of inflammasome pathways, and inhibiting these pathways with ZyVersa's Inflammasome ASC Inhibitor IC 100 showed reduced aortic lesion size in diabetic mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
ZyVersa Therapeutics Inc

Nasdaq:ZVSA

ZVSA Rankings

ZVSA Stock Data

5.39M
7.50M
0.83%
2.65%
7.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Weston

About ZVSA

variant pharmaceuticals is an orphan drug company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases. our accomplished leadership team, each with more than 15 years of demonstrated success in the biopharmaceutical and medical industries, focuses on assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors. our evolving product pipeline is targeted to the $100+ billion orphan drug market. our lead orphan drug candidate is hydroxypropyl beta cyclodextrin (hpβcd) for chronic treatment of two orphan indications, var 200: focal segmental glomerulosclerosis (fsgs) and var 300: alport syndrome (as). both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids, contributing to impaired kidney function, ultimately leading to dialysis and/or kidney transplantation. hpβcd entraps and removes lipids